Surlorian

Phase 2

RRyCarma Therapeutics, Inc.

Surlorian is one of 11 therapeutic programs targeting Myopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

MyopathyRecruiting

MyopathyPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Myopathy

#DrugCompanyPhaseTrials

Viagra

VViatris Specialty LLC

Approved

1 2

Zocor

OOrganon and Co

Approved

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 4

Mesnex

BBaxter Healthcare Corporation

Approved

—5

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—6

Cytoxan

BBaxter Healthcare Corporation

Approved

—7

Dantrium

AAultman Health Foundation

Phase 3

1 8

Salbutamol

GSK

Preclinical

1 9

Surlorian

RRyCarma Therapeutics, Inc.

Phase 2

1 10

Coenzyme Q10

MMclean Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Myopathy

NCT07560020

Clinical

Trials by Indication[1]

Myopathy1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Surlorian (ARM210, S48168) in Adults With Autosomal Dominant RYR1-Related Myopathy

Recruiting·RRyCarma Therapeutics, Inc.·Phase 2·NCT07560020·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Surlorian. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Surlorian. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — RyCarma Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: RRyCarma Therapeutics, Inc.

Surlorian

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Myopathy1 trial

References

Drug Info

Quick Facts

Related News